Rhythm Pharmaceuticals grants inducement RSUs to new employees for rare neuroendocrine diseases treatment.

From GlobeNewswire: 2024-11-13 16:01:00

Rhythm Pharmaceuticals granted inducement RSUs to new employees on November 7, 2024. The RSUs cover an aggregate of 15,750 shares of common stock and vest over four years. Rhythm focuses on rare neuroendocrine diseases and its lead asset, IMCIVREE, is approved by the FDA and EC for treating obesity. Setmelanotide is indicated for certain genetic conditions related to obesity. However, there are limitations and contraindications to its use, including hypersensitivity reactions and disturbances in sexual arousal. Regular monitoring is required for adverse reactions and specific populations, such as lactating women and pediatric patients.

For more information, contact Rhythm Pharmaceuticals at +1 (833) 789-6337 or FDA at 1-800-FDA-1088. See the full U.S. Prescribing Information and EU Summary of Product Characteristics for additional Important Safety Information. This press release contains forward-looking statements regarding the safety, efficacy, and regulatory progress of setmelanotide and other product candidates. Risk factors include clinical trial outcomes, regulatory approvals, competition, and economic conditions. Rhythm Pharmaceuticals has no obligation to update forward-looking statements based on future events or developments.



Read more at GlobeNewswire: Rhythm Pharmaceuticals Announces New Employment Inducement